Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

Presentation ESC 2025

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

August 30, 2025

Presentation Controversies and Advances 2025

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Presenter: Peter P. Toth

January 30, 2025

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation ACC 2024

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Presenter: Steven E. Nissen

April 08, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

Presentation Complex Coronary Cases 2023

Lipid Guidelines and Therapy

Presenter: Icilma Fergus

June 16, 2023

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

Presentation TCT 2022

TCT 577: Lipoprotein (a) and Intracoronary Imaging After Intensive Statin Treatment

Presenter: Shingo Minatoguchi

September 19, 2022

Presentation ACC 2022

TRANSLATE-TIMI 70

Presenter: Brian Bergmark

April 04, 2022

Presentation Controversies and Advances 2021

What Diet is Best for Cardiovascular Health?

Presenter: Kim Allan Williams, Sr.

December 03, 2021

Presentation Controversies and Advances 2021

Pathways for Inflammation in Athero-thrombosis Focus on Inflammasome

Presenter: P. K. Shah

December 03, 2021

Presentation Controversies and Advances 2021

EPA Fish Oil: Who Should Receive It?

Presenter: Peter P. Toth

December 03, 2021

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Advertisement

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Safety and Pharmacodynamic Effects of VERVE-101

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Lipid Guidelines and Therapy

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

TCT 577: Lipoprotein (a) and Intracoronary Imaging After Intensive Statin Treatment

TRANSLATE-TIMI 70

What Diet is Best for Cardiovascular Health?

Pathways for Inflammation in Athero-thrombosis Focus on Inflammasome

EPA Fish Oil: Who Should Receive It?

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content